Associate Professor Natalie Staplin
Natalie Staplin
PhD
Senior Statistician
Natalie is a Senior Statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU). She is also a lecturer on the MSc in Global Health Sciences.
Natalie joined CTSU in 2012 after completing an undergraduate degree in Mathematics with Actuarial Science and a PhD in Statistics.
Her current research interests are epidemiological analyses of patients with chronic kidney disease to identify risk factors associated with vascular events or progression to end-stage renal disease.
She is particularly interested in competing risks methodology and the use of directed acyclic graphs in observational analyses.
Recent publications
-
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
Journal article
HORBY PW. et al, (2025), The Lancet Infectious Diseases
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
-
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
-
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Journal article
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
-
Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
Preprint
Horby PW. et al, (2025)